Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4193 Pivotal role of the multidisciplinary tumor board on the management of neuroendocrine neoplasms – Impact of MTB decisions in an ENETS Center of Excellence

Introduction: Multidisciplinary Tumor Board (MTB) meetings are a valuable tool to improve the management of solid tumors. Yet, few evidences regarding the real-world impact of Neuroendocrine Neoplasm (NEN)-dedicated MTBs are available.

Conference:

Presenting Author:

Authors: Maratta M, Vitale A, Occhipinti D, Raia S, Menotti S,

Keywords: multidisciplinary tumor board, neuroendocrine cancer, disease management, patient care,

#1127 Zebrafish as a New In Vivo Model to Study Angiogenesis in Neuroendocrine Tumors (NET)

Introduction: Zebrafish is a powerful model to study human diseases, including cancer.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Vitale G

Authors: Gaudenzi G, Dicitore A, Cotelli F, Ferone D, Persani L,

Keywords: zebrafish, NET,

#1097 Epigenetic Manipulation of the Somatostatin Receptor Type 2 in Neuroendocrine Tumor Cells

Introduction: The somatostatin receptor type 2 (sst2) is a target for treatment in patients with neuroendocrine tumors (NET). However, variability in tumoral sst2 expression might lead to variability in response. Epidrugs could increase sst2 levels and improve response to somatostatin analogues (SSA).

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Veenstra M, Van Koetsveld P, Dogan F, Farrell W, Vitale G,

Keywords: NET, sst2, epidrug, signaling,

#747 A Single-Center, Open-Label, Phase II, Proof-of-Concept Study with Pasireotide LAR in Patients with Progressive Medullary Thyroid Cancer (MTC): Preliminary Data

Introduction: MTC is a well-differentiated neuroendocrine tumor in which somatostatin receptor (sst) expression is higher for sst1 and sst5 than for sst2. This may explain why the available sst2–selective analogues do not work in these patients and why pasireotide (SOM230), a novel, multi-receptor targeted somatostatin analogue with high-binding affinity for sst1, 2, 3 and sst5 could be effective.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Faggiano A, Ferolla P, Vitale G, Del Prete M, Ramundo V,

Keywords: medullary thyroid cancer, pasireotide, somatostatin receptor,

#586 A Single-Center, Open-Label, Phase II, Proof-of-Concept Study with Pasireotide LAR in patients with progressive medullary thyroid cancer (MTC): preliminary data

Introduction: MTC is a well-differentiated neuroendocrine tumor in which somatostatin receptor (sst) expression is higher for sst1 and sst5 than for sst2.

Conference:

Presenting Author:

Authors: Faggiano A, Ferolla P, Vitale G, Del Prete M, Ramundo V,

Keywords: Pasireotide, medullary thyroid cancer,